Biomedical subjects

Rimvydas Slapikas

Publications and source records attributed to Rimvydas Slapikas.

6 recordsLinked to original sources

PubMed2005

Informative value of clinical markers for the risk of cardiovascular death in postinfarction chronic heart failure.

UNLABELLED: Symptomatic chronic heart failure (CHF) in patients with previous myocardial infarction results in a high risk of death. The aim of the study was to determine the informative value of different clinical markers and their combinations for cardiovascular death risk evaluation in case of CHF after Q-wave myocardial infarction (MI). METHODS: Two hundred and twenty-four patients with congestive heart failure NYHA class II-IV after Q-wave MI were followed-up for five years (median 2.6 +/- 2.0 years). The probability of cardiovascular death was evaluated using Kaplan-Meier curves, the impact of clinical variables on the risk of death, and adjusted risk of death were evaluated using Cox proportional regression method, and the total risk score of death was determined using the multivariate regression method. RESULTS: The probability of cardiovascular death within the first year was 21%, within two years 40%, within three years 55%, within four years 61%, and within five years 65%. According to the risk of death, the independent predictors were allotted a risk score which was determined for all patients and had shown a strong association with 5-year cardiovascular mortality. Patients with a risk score of 9, versus those with a score of 0, were found to have a 15-fold increase in cardiovascular mortality rate. CONCLUSION: The probability of cumulative cardiovascular mortality within five years in case of a symptomatic CHF after Q-wave MI was 65%. In the presence of risk factor combinations, the probability of death within three years reached 98%.

Adult↗

PubMed2005

[Relationship between the metabolic syndrome, endothelial function and intima-media thickness in asymptomatic middle-aged individuals].

OBJECTIVE: To evaluate the relation between cardiovascular risk factors, metabolic syndrome, endothelial function and carotid intima-media thickness in asymptomatic middle-aged individuals. MATERIALS AND METHODS: A total of 180 subjects (86 men and 94 women, mean age 38.8+/-0.3 years) have been investigated. Anthropometric, blood pressure measurements have been performed and lipid as well as high sensitivity C-reactive protein blood levels have been tested. The endothelial function was assessed by measuring the vasodilatation of the brachial artery. The carotid intima-media thickness was measured with high resolution B-mode ultrasound imaging. Metabolic syndrome was diagnosed using International Diabetes Federation definition criteria (2005). RESULTS: The metabolic syndrome has been diagnosed in 48 (26.7%) individuals: 28 (32.6%) males and 20 (21.3%) females. Significantly reduced endothelial function has been established in asymptomatic men when compared to women. However, statistically significant decrease (4.84%) in endothelial function in metabolic individuals was detected only among males. In the metabolic patients intima-media of common carotid artery, carotid bulb and internal carotid artery was thicker than in those without metabolic syndrome (0.006, 0.007 and 0.007 cm, respectively) (alpha=0.000, beta=0.01). Endothelial dysfunction and intima-media thickening correlated with increased blood pressure, abdominal circumference and body mass index as well as with elevated blood triglyceride and glucose levels. Intima-media thickness was greater in individuals with impaired endothelial function in all carotid segments tested. No relationship has been observed between total or low-density lipoprotein cholesterol concentrations and endothelial function, intima-media thickening or high sensitivity C-reactive protein levels. CONCLUSIONS: These observations suggest that the metabolic syndrome and/or its components may influence the different initial mechanisms of atherosclerosis--disorder of endothelial function and intima-media thickening. It is presumable that the lipid disorders as well as inflammation may play more significant role in the presence of impaired endothelial function.

Adult↗

PubMed2005

[The prevalence of metabolic syndrome in middle-aged in Kaunas population].

AIM: To assess the prevalence of the metabolic syndrome among middle-aged Kaunas population. MATERIAL AND METHODS: A total of 433 (192 males and 241 females, mean age 38.8+/-0.3 years) asymptomatic individuals have been investigated. Metabolic syndrome was diagnosed using International Diabetes Federation definition criteria - central obesity (the waist circumference > or =94 cm for men and > or =80 cm for women) plus any two of the following four factors: elevated triglycerides (Tg) (> or =1.7 mmol/L), low high-density lipoprotein cholesterol (HDL-C) levels (<1.0 mmol/L for men and <1.3 mmol/L for women), blood pressure (BP) of 130/85 or higher (systolic pressure >130 mmHg or a diastolic pressure >85 mmHg) or hyperglycemia (> or =5.6 mmol/L). RESULTS: The metabolic syndrome was present in 21.7% (28.1% among males and 16.6% among females) of individuals. Furthermore, 41.1% had an increased waist circumference, 56.4% had elevated BP (130/85 or higher), 31.2% had elevated plasma glucose concentration, 19.9% had low HDL-C cholesterol values and 14.1% had increased Tg values. Significantly higher concentration (1.16 mg/L, alpha<0,001, beta<0.001) of high-sensitivity C-reactive protein has been established in individuals with the metabolic syndrome. An increased concentration (>3 mg/L) of high-sensitivity C-reactive protein was more prevalent (17.3%) in the cohort with metabolic syndrome. Concentration of high-sensitivity C-reactive protein directly correlated with the waist and hips circumference, body mass index, concentration of Tg, glucose and BP. CONCLUSIONS: The prevalence of the metabolic syndrome among middle-aged Kaunas residents was 22%. Metabolic syndrome and central obesity correlated with elevated concentration of high-sensitivity C-reactive protein. Moderately (1-3 mg/L) and severely (>3 mg/L) elevated high-sensitivity C-reactive protein levels increase the chance of metabolic syndrome by 4.15 and 7.39 times, respectively (p=0,000). An innovative approach towards cardiovascular risk assessment integrating traditional cardiovascular risk factors, metabolic syndrome and high-sensitivity C-reactive protein values could improve the risk stratification in asymptomatic middle-aged population.

Adult↗

PubMed2005

[Prevalence of cardiovascular risk factors in coronary heart disease patients with different low-density lipoprotein phenotypes].

UNLABELLED: Low-density lipoprotein (LDL) heterogeneity is now well recognized as an important factor reflecting differences in lipoprotein composition, size, metabolism and genetic influences. There is an abundant evidence of data supporting the clinical importance of small, dense LDL particles in the development of coronary heart disease. The aim of the study was to determine the prevalence of LDL phenotypes A and B in coronary artery disease patients and to assess the incidence of cardiovascular risk factors in groups with different phenotype. MATERIAL AND METHODS: Demographic, anamnestic and clinical data as well as complete lipid profile--total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides--were collected on 1,220 patients (63.7% male and 36.3% female, mean age 61.3+/-11.0 years) with coronary artery disease. Triglycerides/HDL cholesterol ratio was calculated. By value of triglycerides/HDL cholesterol ratio, proposed V. Hanak and authors, the patients were identified as having LDL phenotype A when the ratio was < or =1.64 (a value of 3.8 as expressed in milligrams per deciliter) and phenotype B when the ratio was >1.64. RESULTS: LDL profile in 60.5% of patients was identified as phenotype A and in 39.5%--as phenotype B. The incidence of coronary heart disease risk factors was higher in phenotype B patients as compared to phenotype A subjects (hypertension - 85.1% vs. 75.2%, p<0.001, diabetes mellitus--13.9% vs. 5.5%, p<0.001, obesity--46.7% vs. 28.0%, p<0.001, reduced physical activity--64.5% vs. 57.0%, p<0.001). Metabolic syndrome was present in 85.1% of phenotype B patients, while this cluster of metabolic disorders was detected only in 36.8% of phenotype A subjects. The incidence of myocardial infarction, presence of multiple high-grade coronary lesions were also higher in phenotype B patients as compared to their counterparts with phenotype A (22.2% vs. 17.2%, p<0.05 and 13.7% vs. 8.7%, p<0.05). CONCLUSION: LDL phenotype B was determined in 39.5% of coronary heart disease patients. Atherogenic LDL subclass pattern B correlated with higher incidence of major coronary heart disease risk factors.

Aged↗

PubMed2004

Lethal outcomes in patients with symptomatic heart failure developed after Q-wave myocardial infarction.

The article analyses clinical characteristics and mortality of patients with symptomatic chronic heart failure following Q-wave myocardial infarction. During the study 224 patients (mean age 64.1+/-9.7) with symptomatic chronic heart failure and left ventricular ejection fraction <40% were followed-up for 1-5 years (on the average, 2.6+/-2.0 years). The majority of the studied patients had had anterior or anterior-lower Q-wave myocardial infarction (61.6% and 25.9%, respectively) and an identified Canadian function class II-IV angina pectoris (74.6%), and one-fifth of the patients (19.6%) had unstable angina pectoris. All patients were diagnosed with chronic heart failure New York Heart Association function class II-IV, the majority of patients had disturbances in cardiac rhythm and conduction, almost a half of them (46.0%) had left ventricular aneurysm, 92.8% of patients were diagnosed with marked changes in left ventricular geometry, 84.4% of patients had II-IV degrees mitral regurgitation, a half of the patients had significant left ventricular diastolic dysfunction, and 6.3% of patients had previously experienced thromboembolic complications. During the follow-up period 132 patients died. The comparison of the characteristics of patients who survived with those of patients who died showed that the deceased patients were statistically significantly older compared to survivors; in addition to that, marked stenoses of three coronary arteries, severe chronic heart failure, ejection fraction < or =20%, ventricular extrasystoles, and sinal tachycardia were more common in the former group, and patients who died less frequently were overweight and less frequently used beta adrenoblockers. The evaluation of Kaplan-Meier curves showed that total mortality resulting from the development of chronic heart failure symptoms and indications of chronic heart failure during the 1st year was 21.0%, during the 2nd year -40%, during the 3rd year -55.0%, during the 4th year -61.0%, and during the 5th year -65.0% the highest mortality was observed when left ventricular ejection fraction < or =20%, and age >75. The development of severe chronic heart failure resulted, on the average, after 1.5+/-1.1 years. It is obvious that symptomatic chronic heart failure caused by ischemic cardiomyopathy and marked left ventricular systolic dysfunction following Q-wave myocardial infarction is a rapidly progressing process conditioning high risk of lethal outcome within the period of several years.

Adult↗

PubMed2003

[Low density lipoprotein apheresis].

Increased blood cholesterol concentration is one of the main factors in ischemic heart disease, development of which is determined by atherosclerotic changes in coronary vessels. Diet and treatment with 3-hydroxi-3-metilglutaril coenzyme A (HMG-CoA) reductase inhibitors helps to reduce low density lipoprotein cholesterol (LDL-Ch) blood concentration up to recommended level of 3.0 mmol/l in most patients but in some patients particularly with familial dyslipidemias cholesterol concentration remains increased even after treatment with maximal doses of lipid-regulating agents or their combinations. The most frequently used mechanical methods of cholesterol removal from blood include the procedures of extracorporeal apheresis. Low density lipoprotein (LDL) apheresis not only significantly reduces the blood concentrations of total cholesterol (TCh), and LDL-Ch, lipoprotein (a) (Lp(a) and fibrinogen but also stops the progression of atherosclerosis in coronary vessels.

Adult↗